Product DemonstrationsLife Sciences
TransIT BrCa Transfection Reagent
21 Oct 2014
Watch this video to learn more about the TransIT-BrCa Transfection Reagent, the first dedicated breast cancer cell line specific reagent. While it delivers efficiently to many breast cancer cell types, it also maintains low cellular toxicity resulting in reduced experimental biases.
About the company
Mirus Bio LLC
Mirus Bio LLC is a life science company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products.
Mirus R&D uniquely integrates nucleic acid delivery and chemistry, a core competency which is unmatched in the industry. This serves as the foundation for its novel research reagents.

